Abcam plc
General Information | |
Business: | (Please note: This is not an IPO. The listing here is a professional courtesy. IPOScoop has No Call on this offering of American Depositary Shares (ADS). This is a step-up listing, also known as an uplift, to the NASDAQ from the AIM of the London Stock Exchange. The uplift offering was priced at $17.50 per ADS.) (From the prospectus: “Since 2005, our ordinary shares have traded on the AIM market of the London Stock Exchange, under the symbol “ABC.” On October 15, 2020, the last reported sale price of our ordinary shares on AIM was £12.80 per ordinary share (equivalent to $16.52 per ADS based on an assumed exchange rate of £1.00 to $1.2909).” ) We are a global life science company focused on identifying, developing and distributing high-quality reagents and tools for our customers at the forefront of life science research. Our products are used by researchers to study biological pathways, which is critical for scientific research, diagnostics and drug discovery. Our mission is to provide life science researchers with highly validated products and services to advance biological research and achieve their goals faster. We do this by continuously innovating and providing our customers with high-quality tools, together with expert customer support. Our product offering includes an extensive portfolio of antibodies and related protein research tools that are fundamental to our customers’ research and experimental workflow. Our customers are primarily scientists and researchers in academic institutions, research institutes and pharmaceutical, biotechnology and diagnostics companies. Headquartered in Cambridge, United Kingdom, we operate across 15 locations around the world, supported by our world-class team of approximately 1,500 employees, including over 200 with PhDs, and have served customers in over 130 countries. **Revenue and profit figures are for the fiscal year ended June 30, 2020, according to the prospectus. In addition to its U.K. headquarters in Cambridge, Abcam plc has a U.S. headquarters in Cambridge, Massachusetts.
|
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 1500 |
Founded: | 1998 |
Contact Information | |
Address | Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom |
Phone Number | +44 (0) 1223 696000 |
Web Address | http://www.abcam.com/ |
View Prospectus: | Abcam plc |
Financial Information | |
Market Cap | $3719.8mil |
Revenues | $321.6 mil (last 12 months) |
Net Income | $15.5 mil (last 12 months) |
IPO Profile | |
Symbol | ABCM |
Exchange | NASDAQ |
Shares (millions): | 9.0 |
Price range | $17.50 - $17.50 |
Est. $ Volume | $156.5 mil |
Manager / Joint Managers | Morgan Stanley/ BofA Securities/ SVB Leerink/ Lazard/ William Blair |
CO-Managers | |
Expected To Trade: | 10/22/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |